New registry aims to unlock secrets of rare skin disease GPP
NCT ID NCT06100991
First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times
Summary
This study is a registry that will follow about 200 people with generalized pustular psoriasis (GPP) across North America. Researchers want to learn more about how GPP develops, how it is managed, and what happens to patients over time. Participants will be under the care of a dermatologist and will provide information about their condition and treatments. This is an observational study, meaning no new drugs or treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could provide valuable insights into how GPP behaves and is treated, potentially guiding future research and care.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may take years and might not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2023
- Expected to finish
-
Dec 2099
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects are enrolled in the GPP Registry during regularly scheduled office visits. Selected dermatologists are invited to participate as investigators in the Registry.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A subject must meet all the following criteria to participate in the registry: 1. Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner. 2. Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted. 3. Is willing to provide consent for participation in the registry. 4. Is willing to provide Personal Information Exclusion Criteria: * Any of the following would exclude the subject from participating in the registry: 1. Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP. 2. Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Generalized pustular psoriasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CorEvitas, LLC
RECRUITINGWaltham, Massachusetts, 02451, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Costa rica launches national registry to track rare skin disease
- New injection aims to stop dangerous psoriasis flares in their tracks
- New drug spesolimab under Real-World watch for rare skin disease
- Psoriasis flare drug study pulled before it began
- New pill shows promise for rare, severe psoriasis
- Can a single infusion stop GPP flares in their tracks?